Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Fennec Pharmaceuticals Inc (FENC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: FENC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.8
1 Year Target Price $12.8
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 37.29% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 229.24M USD | Price to earnings Ratio - | 1Y Target Price 12.8 |
Price to earnings Ratio - | 1Y Target Price 12.8 | ||
Volume (30-day avg) 5 | Beta 0.4 | 52 Weeks Range 3.96 - 8.72 | Updated Date 07/2/2025 |
52 Weeks Range 3.96 - 8.72 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -46.71% | Operating Margin (TTM) -9.23% |
Management Effectiveness
Return on Assets (TTM) -12.96% | Return on Equity (TTM) -1005.59% |
Valuation
Trailing PE - | Forward PE 11.93 | Enterprise Value 224553916 | Price to Sales(TTM) 7.42 |
Enterprise Value 224553916 | Price to Sales(TTM) 7.42 | ||
Enterprise Value to Revenue 7.26 | Enterprise Value to EBITDA 20.27 | Shares Outstanding 27618700 | Shares Floating 14382184 |
Shares Outstanding 27618700 | Shares Floating 14382184 | ||
Percent Insiders 16.3 | Percent Institutions 57.51 |
Upturn AI SWOT
Fennec Pharmaceuticals Inc
Company Overview
History and Background
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for pediatric cancers. Founded in 1996, they are dedicated to developing and commercializing innovative treatments for children suffering from cancer. The company has evolved to focus on its lead product, PEDMARKu2122 (sodium thiosulfate) for ototoxicity associated with cisplatin chemotherapy.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of pharmaceutical products, with a primary focus on PEDMARKu2122.
Leadership and Structure
Fennec Pharmaceuticals Inc. is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure is centered around research, clinical development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- PEDMARKu2122 (Sodium Thiosulfate): PEDMARKu2122 is indicated to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients 1 month to <18 years of age with localized, non-metastatic solid tumors. Fennec has exclusive worldwide rights to PEDMARK. Competitors include supportive care strategies aimed at managing ototoxicity, but PEDMARK is the only FDA-approved drug for prevention.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and dynamic, with significant research and development investment. The market for pediatric oncology therapies is growing due to increased awareness and advancements in treatment options.
Positioning
Fennec Pharmaceuticals Inc. is positioned as a specialized biopharmaceutical company focused on addressing unmet needs in pediatric oncology, particularly in preventing chemotherapy-induced ototoxicity. Their competitive advantage lies in the exclusivity and FDA approval of PEDMARKu2122.
Total Addressable Market (TAM)
The estimated total addressable market is dependent on incidence of cisplatin use in pediatric cancer patients and the adoption rate of PEDMARKu2122. Estimates range from $200M to $400M annually. Fennec is positioned to capture a significant portion of this TAM with successful commercialization.
Upturn SWOT Analysis
Strengths
- FDA approval of PEDMARKu2122
- Exclusive worldwide rights to PEDMARKu2122
- Focus on unmet needs in pediatric oncology
- Experienced management team
Weaknesses
- Sole product dependency
- Reliance on successful commercialization of PEDMARKu2122
- Small market capitalization
- History of regulatory delays
Opportunities
- Expansion of PEDMARKu2122 label to other indications
- Partnerships for commercialization and distribution
- Geographic expansion
- Acquisition or in-licensing of other pediatric oncology assets
Threats
- Competition from alternative therapies or new drugs
- Regulatory challenges and delays
- Reimbursement pressures
- Clinical trial setbacks
Competitors and Market Share
Key Competitors
Competitive Landscape
Fennec Pharmaceuticals Inc.u2019s advantages lie in its exclusive FDA-approved product. Disadvantages include limited resources and dependence on PEDMARKu2122 success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its development stage and lack of commercially available products until recently.
Future Projections: Future growth is contingent on the successful commercialization of PEDMARKu2122 and potential expansion into new markets or indications. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the commercial launch of PEDMARKu2122 and efforts to secure reimbursement and market access.
Summary
Fennec Pharmaceuticals is focused on pediatric oncology with its lead product, PEDMARKu2122, poised to become a standard of care. Its main strengths are PEDMARK's exclusivity and focus on an unmet need. However, the company faces the challenge of commercialization success and reliance on a single product. Fennec needs to effectively navigate the competitive landscape and regulatory environment to achieve its growth objectives.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fennec Pharmaceuticals Inc. corporate website
- SEC filings
- Press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share comparison data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fennec Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 2001-06-05 | CEO & Director Mr. Jeffrey S. Hackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://fennecpharma.com |
Full time employees 32 | Website https://fennecpharma.com | ||
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.